Results 101 to 110 of about 355,709 (346)

Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk

Advanced Healthcare Materials, EarlyView.
Centralizes the microbiome within 3D tumor‐microbiome model platforms, including spheroids, organoids, 3D‐bioprinted constructs, and microfluidic chips, each enabling structured host‐tumor‐microbe studies. These systems support bacterial colonization, facilitating investigation of microbial impacts on tumor growth, immunity, and therapy. The microbiome
Marina Green Buzhor, Giuseppe Longobardi, Or Kandli, Anne Krinsky, Opal Avramoff, Anshika Katyal, Koren Salomon, Adan Miari, Dana Venkert, Tania T. Barnatan, América García Alvarado, Shahar Greenberg, Ronit Satchi‐Fainaro   +12 more
wiley   +1 more source

Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule

OncoImmunology, 2020
We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advanced non-small-cell lung cancer (NSCLC) patients. A phase III trial was designed using an optimized immunization schedule.
Xitlally Popa, Beatriz García, Karla P. Fuentes, Vivian Huerta, Karen Alvarez, Carmen E. Viada, Elia Neninger, Pedro C. Rodríguez, Zuyen González, Amnely González, Tania Crombet, Zaima Mazorra   +11 more
doaj   +1 more source

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Clinical Cancer Research, 2016
Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC) harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) experience disease progression during treatment due to brain metastases. Despite
P. Ballard, J. Yates, Zhenfan Yang, Dong-Wan Kim, J. Yang, M. Cantarini, K. Pickup, Angela Jordan, Mike Hickey, Matthew Grist, Matthew R. Box, P. Johnström, K. Varnäs, J. Malmquist, K. Thress, P. Jänne, D. Cross   +16 more
semanticscholar   +1 more source

MUTE‐Seq: An Ultrasensitive Method for Detecting Low‐Frequency Mutations in cfDNA With Engineered Advanced‐Fidelity FnCas9

Advanced Materials, EarlyView.
An advanced‐fidelity CRISPR nuclease, FnCas9‐AF2, is rationally engineered to discriminate single‐base mismatches with unprecedented level precision. Integrated into the MUTE‐Seq workflow, FnCas9‐AF2 depletes wild‐type cell‐free DNA, thereby exposing rare tumor‐derived mutant DNA (a molecular “needle in a haystack”).
Sunghyeok Ye, Jin‐Soo Kim, Myungshin Kim, Ki‐Yeon Kim, Yoon‐Ho Won, Taegun Park, Sungjae An, Haerin Jeong, Hee‐Joon Chung, In Seon Lee, Myoung‐Hee Kang, Chan Young Kang, Mi Young Kim, Jae Ho Chung, Jeong‐An Gim, Woochang Hwang, Yonggoo Kim, Song Cheol Kim, Sungho Lee, Junho K Hur, Junseok W Hur   +20 more
wiley   +1 more source

Advances and Strategies in Enhancing mRNA Cancer Vaccines

Advanced Materials, EarlyView.
Messenger RNA (mRNA) vaccines offer a powerful approach for cancer immunotherapy, but their clinical impact remains limited by delivery challenges and suboptimal immune activation. This review discusses key biological barriers and design strategies—including structural optimization, immunomodulation, organ targeting delivery, and advanced nanocarriers ...
Miao Zhang, Shengqi Chen, Haijun Hu, Yenhui Ong, Qianqian Ni   +4 more
wiley   +1 more source

Prognostic significance of tumor microenvironment assessed by machine learning algorithm in surgically resected non‐small cell lung cancer

Cancer Reports, EarlyView., 2023
Abstract Background A methodology to assess the immune microenvironment (IME) of non‐small cell lung cancer (NSCLC) has not been established, and the prognostic impact of IME factors is not yet clear. Aims This study aimed to assess the IME factors and evaluate their prognostic values. Methods and Results We assessed CD8+ tumor‐infiltrating lymphocyte (
Yukihiro Terada, Mitsuhiro Isaka, Akira Ono, Takuya Kawata, Masakuni Serizawa, Keita Mori, Koji Muramatsu, Kiyoshi Tone, Hirotsugu Kenmotsu, Keiichi Ohshima, Kenichi Urakami, Takeshi Nagashima, Masatoshi Kusuhara, Yasuto Akiyama, Takashi Sugino, Toshiaki Takahashi, Yasuhisa Ohde   +16 more
wiley   +1 more source

Cancer Cells Traverse Faster in Confined Space by Modifying Vimentin filaments With Nuclear Deformation and Promoting the Growth of Desired Tumor Spheroids

Advanced Materials Interfaces, EarlyView.
This study demonstrates how the Vimentin intermediate (VIM) filaments distribution/density regulates the attainment of different migration modes through cytoskeleton rearrangement and controls the nuclear morphology in migrating cells under physical confinement, which facilitates the faster traversing of those cells and the growth of post‐migration ...
Md Kowsar Alam, Jiao Zhai, Heng Zou, Yu Chen, Michael Yang   +4 more
wiley   +1 more source

CCL5hi Macrophages Interact with CD8+ T Cells and Potentiate Responsiveness to PD‐1 Blockade Plus Chemotherapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
This study has characterized a functionally distinct macrophage subset, termed CCL5hi macrophages, and elucidated the underlying mechanisms of a regulatory feedback loop that interconnects IFN‐γ, CCL5hi macrophages, and CD8+ T cells within the TME of ESCC undergoing immunochemotherapy.
Yuanzhen Ma, Xiaodong Su, Tingting Zeng, Chunlian Zhou, Guozhen Yang, Zengfei Xia, Chufeng Zeng, Jiarong Zhan, Xin‐Yuan Guan, Xu Zhang, Yan Li   +10 more
wiley   +1 more source

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

Clinical Cancer Research, 2018
Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC.
X. Le, S. Puri, M. Negrão, M. Nilsson, J. Robichaux, T. Boyle, J. K. Hicks, Katherine Lovinger, Emily B. Roarty, W. Rinsurongkawong, M. Tang, Huiying Sun, Y. Elamin, Lara Lacerda, J. Lewis, J. Roth, S. Swisher, J. Lee, W. William, B. Glisson, Jianjun Zhang, V. Papadimitrakopoulou, J. Gray, J. Heymach   +23 more
semanticscholar   +1 more source

NNT in NSCLC: No need to worry?

Journal of Experimental Medicine, 2020
In this study, Ward et al. (https://doi.org/10.1084/jem.20191689) provide exciting evidence that nucleotide nicotinamide transhydrogenase (NNT), a mitochondrial matrix–located enzyme harnessing the proton gradient to generate NADPH using NADH, markedly contributes to non-small cell lung carcinoma (NSCLC), which is abrogated in the murine C57BL/6J ...
openaire   +4 more sources